Evaluation of vancomycin dosing regimens in preterm and term neonates using monte carlo simulations

Pharmacotherapy

Volumn 32, Issue 5, 2012, Pages 408-419

  Mehrotra, Nitin ^a   Tang, Lisa ^a   Phelps, Stephanie J ^b   Meibohm, Bernd ^a  

^a Departments of Pharmaceutical Sciences   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Dosing recommendations; Modeling and simulation; Pediatrics; Pharmacokinetics; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; CEFOTAXIME; CEFTRIAXONE; CREATININE; VANCOMYCIN;

AGE DISTRIBUTION; ALGORITHM; ARTICLE; BIRTH WEIGHT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NEWBORN; NEWBORN CARE; PERINATAL PERIOD; POSTNATAL GROWTH; PREMATURITY; PRENATAL GROWTH; PROBABILITY; RETROSPECTIVE STUDY; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84864629155     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01029.x     Document Type: Article

References (26)

1. Hall SL. Coagulase-negative staphylococcal infections in neonates. Pediatr Infect Dis J 1991;10:57-67.
2. Spears RL, Koch R. The use of vancomycin in pediatrics. Antibiot Annu 1959;7:798-803.
3. de Hoog M, Mouton JW, van den Anker JN. Vancomycin: Pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 2004;43:417-40.
4. Nelson JD, Bradley JS. Nelsons pocketbook of pediatric antimicrobial therapy, 14th ed. Baltimore, MD: Williams & Wilkins, 2000-2001.
5. James A, Koren G, Milliken J, Soldin S, Prober C. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987;31:52-4.
6. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988;35:637-42.
7. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995;17:319-26.
8. Young T, Mangum B. Neofax: A manual for drugs used in neonatal care, 19th ed. Raleigh, NC: Acorn Publishing, 2006.
9. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001;41:927-34.
10. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 1999;81:F221-7.
11. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
12. Phelps S, Hak E, Crill C, eds. Pediatric injectable drugs, 9th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2010.
13. Jonsson EN, Karlsson MO. Xpose-An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999;58:51-64.
14. Wilkins JJ. NONMEMory: A run management tool for NONMEM. Comput Methods Programs Biomed 2005;78:259-67.
15. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: Issues in design and analysis. AAPS J 2005;7:E475-87.
16. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000;314:1-27.
17. Casey PH, Kraemer HC, Bernbaum J, Yogman MW, Sells JC. Growth status and growth rates of a varied sample of low birth weight, preterm infants: A longitudinal cohort from birth to three years of age. J Pediatr 1991;119:599-605.
18. Ehrenkranz RA, Younes N, Lemons JA, et al. Longitudinal growth of hospitalized very low birth weight infants. Pediatrics 1999;104:280-9.
19. Guo SS, Roche AF, Chumlea WC, Casey PH, Moore WM. Growth in weight, recumbent length, and head circumference for preterm low-birthweight infants during the first three years of life using gestation-Adjusted ages. Early Hum Dev 1997;47:305-25.
20. Guo SS, Wholihan K, Roche AF, Chumlea WC, Casey PH. Weight-for-length reference data for preterm, low-birth-weight infants. Arch Pediatr Adolesc Med 1996;150:964-70.
21. Roche AF, Guo SS, Wholihan K, Casey PH. Reference data for head circumference-for-length in preterm low-birth-weight infants. Arch Pediatr Adolesc Med 1997;151:50-7.
22. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: Modelling covariate effects. Eur J Pediatr 2006;165:819-29.
23. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996;30:329-32.
24. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997;276:122-6.
25. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009;24:67-76.
26. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 2000;67:360-7.